Medical Marijuana, Inc. Portfolio Investment Firm Kannalife, Inc. Receives Patent in Australia for Its Novel Monotherapeutic Substances to Treat CNS and PNS Disorders
SAN DIEGO, March 19, 2020/ PRNewswire/– Medical Marijuana, Inc.( OTC: MJNA) (the “Business”), the first-ever openly traded marijuana business in the United States that released the world’s first-ever cannabis-derived nutraceutical items, brands and supply chain, announced today that its portfolio investment firm Kannalife, Inc.(” Kannalife”) (OTCQB: KLFE) has been issued Australian Patent AU2015204609 B2(the “Patent”) particular to “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy.” With this Patent, Kannalife now holds seven patents across the globe.
” Medical Marijuana, Inc. and our portfolio of companies such as Kannalife are devoted to expanding knowledge and approval of marijuana and cannabinoid-related studies worldwide,” said Dr. Stuart Titus, CEO of Medical Cannabis, Inc. “Kannalife is pushing forward that goal with new patents in six countries.”
KLS-13019 leads Kannalife’s intellectual property estate of novel, monotherapeutic particles (” KLS Household”), which are capable of acting as neuroprotective representatives and have the possible to treat a series of diseases, consisting of nerve system, oxidative tension, and neurodegenerative disorders.
” With this Patent, we are honored that numerous jurisdictions have actually recognized our IP estate as unique and proprietary,” said Dean Petkanas, CEO of Kannalife. “We see this as an essential step towards commercializing our lead drug candidate KLS-13019 in numerous markets in the future, including the Australian pharmaceutical market, which is anticipated to reach $321 billion in 2020 alone.”
Of the 7 patents released to Kannalife on this technology, 2 are U.S. patents and 5 are foreign patents declaring top priority to Kannalife’s initial 2014 U.S. filing date through global application PCT/US2015/010827, which was published as WO2015/106108 A2 entitled, “Unique Functionalized 1,3-Benzene Diols and their Technique of Usage for the Treatment of Hepatic Encephalopathy” (the “PCT Patent”).
Furthermore, Kannalife has nationwide phase patent applications based on the PCT Patent application pending in Canada, Brazil and India
KLS-13019 is Kannalife’s leading proprietary, investigational, unique, monotherapeutic item for the prospective treatment of a series of neurodegenerative and neuropathic pain conditions, starting with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has actually not been evaluated or approved for client usage by the U.S. Fda (FDA) or any other healthcare authority worldwide. It’s security and effectiveness have not been verified by FDA-approved research study.
About Kannalife, Inc.
Kannalife, Inc. is a biopharmaceutical med-chem company focused on the development of exclusive and trademarked novel monotherapeutic particles for clients experiencing unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy brought on by toxic chemotherapeutic representatives; hepatic encephalopathy (HE), a neurotoxic brain-liver condition brought on by extreme concentrations of ammonia and ethanol in the brain; mild terrible brain injury (mTBI), a disorder connected with single and recurring effect injuries; and chronic distressing encephalopathy (CTE), an illness related to highly repeated effect injuries in professional and amateur sports.
The Company’s KLS Family of proprietary particles focuses on treating oxidative stress-related diseases such as HE, persistent discomfort from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife performs its research study and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
About Medical Marijuana, Inc.
We are a business of firsts ® Medical Cannabis, Inc.( MJNA ) is a cannabis company with three distinct service systems in the non-psychoactive cannabinoid space: an international portfolio of cannabinoid-based nutraceutical brand names led by Kannaway ® and HempMeds ®; a pioneer in sourcing the first-rate legal non-psychoactive marijuana items stemmed from commercial hemp; and a cannabinoid-based clinical research study and botanical drug advancement sector led by its pharmaceutical investment companies and partners consisting of AXIM ® Biotechnologies, Inc and Kannalife, Inc Medical Cannabis, Inc. was named a leading CBD producer by CNBC Medical Cannabis, Inc. was also the very first company to get historic import permits for CBD items from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the advancement of global markets. The business’s flagship item Real Scientific Hemp Oil has actually been utilized in a number of successful medical research studies throughout Mexico and Brazil to comprehend its safety and efficacy.
Medical Marijuana, Inc.’s head office is in San Diego, California, and additional information is offered at OTCMarkets.com or by going to www.medicalmarijuanainc.com To see Medical Cannabis, Inc.’s corporate video, click here
Investors and customers are also encouraged to purchase CBD oil and other products at Medical Marijuana, Inc.’s store.
This press release might contain particular forward-looking statements and information, as defined within the significance of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor produced by those areas. This material contains declarations about predicted future occasions and/or financial outcomes that are positive in nature and topic to risks and unpredictabilities. Such forward-looking statements by definition involve threats, uncertainties and other aspects, which might cause the real results, efficiency or achievements of Medical Cannabis, Inc. to be materially various from the declarations made herein.
FDA (FDA) DISCLOSURE
These declarations have actually not been assessed by the Fda. This item is not planned to detect, treat, cure, or avoid any disease.
Medical Marijuana, Inc. does not offer or distribute any products that remain in violation of the United States Controlled Substances Act.
Financier Relations Contact:
P. (858) 283-4016
View initial material: http://www.prnewswire.com/news-releases/medical-marijuana-inc-portfolio-investment-company-kannalife-inc-receives-patent-in-australia-for-its-novel-monotherapeutic-compounds-to-treat-cns-and-pns-disorders-301026689 html
SOURCE Medical Marijuana, Inc.